Table 2.
Baseline characteristics of patients by treatment regimen.
| Parameters | IC (N = 240) | HMAs (N = 43) | HMAs + chemo (N = 91) | AZA + VEN (N = 183) | Others (N = 28) | p-value |
|---|---|---|---|---|---|---|
| Median age, year (range) | 64 (60–77) | 70 (61–82) | 67 (60–80) | 70 (60–91) | 67 (60–80) | <0.0001 |
| Male, n (%) | 152 (63.3) | 31 (72.1) | 57 (62.6) | 110 (60.1) | 18 (64.3) | <0.0001 |
| s-AML/t-AML, n (%) | 21 (8.8) | 19 (44.2) | 34 (37.4) | 41 (22.4) | 7 (25.0) | <0.0001 |
| Median WBC, 109/L (range) | 24.86 (0.42–312.20) | 3.35 (0.46–138.00) | 4.36 (0.19–324.30) | 6.50 (0.03–328.40) | 2.08 (0.57–200.80) | <0.0001 |
| Median HB, g/L (range) | 77 (29–145) | 76 (46–119) | 69 (25–144) | 68 (28–127) | 67 (46–108) | 0.0013 |
| Median PLT, 109/L (range) | 46 (1–360) | 48 (5–340) | 45 (2–557) | 42 (2–767) | 43 (11–367) | 0.5593 |
| Median LDH, IU/L (range) | 408 (77–3,657) | 240 (103–1,683) | 274 (113–2,714) | 312 (115–6,432) | 302 (143–1,532) | 0.0288 |
| Median BM blast, % (range) | 71.0 (20.0–99.0) | 34.0 (17.0–93.0) | 44.5 (11.5–87.0) | 50.5 (12.0–98.5) | 70.0 (20.0–98.0) | <0.0001 |
| Risk classification by genetics1, n (%) | ||||||
| Favorable | 65 (27.2) | 7 (16.7) | 14 (15.4) | 22 (12.1) | 0 (0) | <0.0001 |
| Intermediate | 72 (30.1) | 11 (26.2) | 22 (24.2) | 41 (22.5) | 10 (35.7) | 0.2233 |
| Adverse | 102 (42.7) | 24 (57.1) | 55 (60.4) | 119 (65.4) | 18 (64.3) | <0.0001 |
IC, intensive chemotherapy; HMA, hypomethylating agent; AZA, azacitidine; VEN, venetoclax; AML, acute myeloid leukemia; WBC, white blood cell; HB, hemoglobin; PLT, platelet; LDH, lactate dehydrogenase; BM, bone marrow. 1Due to various reasons, including bone marrow sample clotting, testing conducted at external hospitals, and the absence of specific tests, some patients were unable to obtain results for karyotype analysis and fusion genes, resulting the risk classification by genetics was unavailable.